Big Pharma’s China Deal Wave & 12 Companies on Our Radar
A snap look at some of the deal dynamics and company platforms pulling global pharma toward China.
In late January, AstraZeneca announced a $15B investment in China through 2030, expanding R&D on Chinese soil with more manufacturing, and a focus on cell therapies and radioconjugates. The expansion builds on AstraZeneca’s long-running China footprint, which began in 1993 and currently runs two R&D centers in Shanghai and Beijing.
In this issue: From Generics to Innovation — Five Growth Stats — Company Radar — Rise & Constraints
Read this Pro article free
Subscribe to BiopharmaTrend Insider, our free biweekly briefing on what matters in tech and bio, and get one free Pro article every month, starting with this one.
Insider arrives every two weeks, plus a short note when we publish a new deep dive. Unsubscribe anytime. Articles you unlock stay unlocked.